

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR OF THE SECOND SESSION OF THE SUPERVISORY COMMITTEE

This announcement is made by Qyuns Therapeutics Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

At the employee representative meeting of the Company held on October 24, 2024, Ms. Wang Yujiao (“**Ms. Wang**”) was re-elected as an employee representative supervisor (the “**Supervisor**”), and will form the second session of the supervisory committee of the Company (the “**Supervisory Committee**”) together with the non-employee representative Supervisors elected at the 2024 extraordinary general meeting. The employee representative Supervisor shall serve a term of three years with effect from the date of election at the employee representative meeting.

Biographical details of Ms. Wang are set out below:

Ms. Wang Yujiao (王玉姣), aged 43, was appointed as our Supervisor on September 17, 2021. She served as our director of human resources and management from April 2018 to April 2021 and has been serving as the assistant to general manager since April 2021. She is primarily responsible for supervising and providing independent advice to our Board.

Ms. Wang joined the Group in June 2015 and has successively served various positions within the Group, including as: (i) a supervisor of the Company from June 2015 to August 2020, where she was mainly responsible for supervising and providing independent advice to the Company; (ii) a deputy director of the integrated affairs department of the Company from June 2015 to April 2018 and a director of human resources and management of the Company from April 2018 to April 2021 and she has been mainly responsible for the management of human resources and administrative affairs; (iii) an assistant to general manager of the Company since April 2021 and has been mainly responsible for the daily affairs management of the board of directors and shareholders’ meeting, and the management of human resources and administrative affairs; and (iv) a supervisor of Cellularforce since April 2023, mainly responsible for supervision and provision of independent opinions to Cellularforce.

Prior to joining the Group, from July 2006 to March 2015, Ms. Wang worked at Hangzhou Genewave Biotechnology Co., Ltd. (杭州基偉生物技術有限公司) which is a subsidiary of Jiangsu T-mab BioPharma Co., Ltd. (江蘇泰康生物醫藥有限公司) (“**Jiangsu T-mab**”). From July 2008 to March 2015, Ms. Wang served as the registration manager at Jiangsu T-mab, where she was primarily responsible for drug registration, preclinical animal testing project management, regulatory filing and survey research.

Ms. Wang graduated from Zhejiang University of Technology (浙江工業大學) in the PRC with a bachelor’s degree in biopharmaceutical science in June 2003 and a master’s degree in biochemical engineering in June 2006. She was qualified as a senior engineer (高級工程師) by Human Resources and Social Security Department of Jiangsu Province (江蘇省人力資源和社會保障廳) in September 2015.

The Company will enter into a Supervisor service contract with Ms. Wang. During her term of office, Ms. Wang will not receive remuneration as a Supervisor but will continue to receive remuneration as an employee of the Company, unless otherwise provided in the remuneration package for Supervisors of the Company.

As at the date of this announcement, to the best knowledge of the Directors and save as disclosed above, Ms. Wang did not hold any directorships in other listed companies in the past three years and has no other major appointments and professional qualifications, and does not have any relationship with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company or any of its subsidiaries.

As at the date of this announcement, Ms. Wang holds approximately 5.72% interest in Xinfu Tongxin. As at the date of this announcement, to the best knowledge of the Directors and save as disclosed above, Ms. Wang does not have any interests or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, the Board of the Company is not aware of any other information in relation to the appointment of Ms. Wang that is required to be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters regarding the appointment of Ms. Wang that need to be brought to the attention of the Shareholders of the Company.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the meanings set out below:

“Board”	the board of Directors of the Company
“Cellularforce”	Jiangsu Cellularforce Biopharma Co., Ltd. (江蘇賽孚士生物技術有限公司), a company established in the PRC with limited liability on August 2, 2018 and an indirect non-wholly owned subsidiary of the Company which is owned as to 66% by Saifu Juli and 34% by Taizhou Huacheng

“Company”	Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥股份有限公司) (formerly known as Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥有限公司)), a company established in the PRC with limited liability in the PRC in 2015, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 2509)
“Director(s)”	the director(s) of the Company
“Group”	the Company and all of our subsidiaries or, where the context so requires, in respect of the period before the Company became the holding company of our present subsidiaries, the business operated by such subsidiaries or their predecessors (as the case may be)
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented or otherwise modified from time to time
“PRC” or “mainland China”	the People’s Republic of China and for the purpose of this announcement only, excluding Hong Kong, the Macau Special Administrative Region and Taiwan, the PRC
“RMB”	Renminbi, the lawful currency of the PRC
“Saifu Juli”	Taizhou Saifu Juli Biomedical Co., Ltd. (泰州市賽孚聚力生物醫藥有限公司), a company established in the PRC with limited liability on July 6, 2018 and a direct wholly owned subsidiary of the Company
“Share(s)”	ordinary share(s) of RMB1.00 each in the capital of the Company
“Shareholder(s)”	holder(s) of Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited, a wholly owned subsidiary of Hong Kong Exchange and Clearing Limited
“subsidiary(ies)”	has the meaning ascribed to it under the Listing Rules
“Supervisor(s)”	the supervisor(s) of the Company

“Supervisory Committee”	the supervisory committee of the Company
“Taizhou Huacheng”	Taizhou Huacheng Medical Investment Group Co., Ltd. (泰州華誠醫學投資集團有限公司), a company established in the PRC and controlled by Taizhou Medicine City Holding Group Co., Ltd. (泰州醫藥城控股集團有限公司), a company wholly owned by the Management Committee of Taizhou Medical New and High-tech Industrial Development Zone (泰州醫藥高新技術產業開發區管理委員會), which is an administrative agency of Jiangsu Provincial Committee of the Communist Party of China (中國共產黨江蘇省委員會) and Jiangsu Provincial People’s Government (江蘇省人民政府)
“Xinfu Quanxin”	Taizhou Xinfu Quanxin Enterprise Management Partnership (Limited Partnership) (泰州信孚全心企業管理合夥企業(有限合夥)), a limited partnership established in the PRC on February 27, 2023, which is owned as to approximately 0.56% by Mr. Wu Yiliang, our executive Director and executive deputy general manager of Cellularforce as its general partner and approximately 99.44% by 27 employees of the Group as its limited partners, and is one of our employee share incentive platforms
“Xinfu Tongxin”	Taizhou Xinfu Tongxin Enterprise Management Partnership (Limited Partnership) (泰州信孚同心企業管理合夥企業(有限合夥)), a limited partnership established in the PRC on August 19, 2021, which is owned as to approximately 8.27% by Mr. Qiu Jiwan as its general partner, approximately 11.38% by Xinfu Quanxin as one of its limited partners and approximately 80.35% by 37 employees of the Group as its limited partners, and is one of our employee share incentive platforms and one of our controlling shareholders

By order of the Board
Qyuns Therapeutics Co., Ltd.
Qiu Jiwan

Chairman of the Board and Executive Director

Hong Kong, October 24, 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi, Mr. Wu Zhiqiang and Dr. Xue Mingyu as non-executive directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive directors.